Stock DNA
Pharmaceuticals & Biotechnology
CNY 14,076 Million (Large Cap)
22.00
NA
0.00%
-0.39
17.21%
3.78
Revenue and Profits:
Net Sales:
641 Million
(Quarterly Results - Mar 2026)
Net Profit:
162 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.55%
0%
3.55%
6 Months
-15.24%
0%
-15.24%
1 Year
18.28%
0%
18.28%
2 Years
57.31%
0%
57.31%
3 Years
37.82%
0%
37.82%
4 Years
12.73%
0%
12.73%
5 Years
-45.1%
0%
-45.1%
Double Medical Technology, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.52%
EBIT Growth (5y)
-2.29%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.58
Tax Ratio
10.39%
Dividend Payout Ratio
40.70%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.11%
ROE (avg)
13.80%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
3.78
EV to EBIT
20.15
EV to EBITDA
15.65
EV to Capital Employed
5.56
EV to Sales
4.69
PEG Ratio
0.43
Dividend Yield
NA
ROCE (Latest)
27.58%
ROE (Latest)
17.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
641.50
724.60
-11.47%
Operating Profit (PBDIT) excl Other Income
167.90
220.40
-23.82%
Interest
1.30
1.30
Exceptional Items
10.60
5.80
82.76%
Consolidate Net Profit
161.90
188.10
-13.93%
Operating Profit Margin (Excl OI)
261.80%
221.80%
4.00%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -11.47% vs 8.83% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -13.93% vs -0.79% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,571.30
2,116.50
21.49%
Operating Profit (PBDIT) excl Other Income
806.10
545.80
47.69%
Interest
6.90
6.90
Exceptional Items
43.90
3.60
1,119.44%
Consolidate Net Profit
636.90
385.30
65.30%
Operating Profit Margin (Excl OI)
219.70%
152.90%
6.68%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 21.49% vs 38.84% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 65.30% vs 346.47% in Dec 2024
About Double Medical Technology, Inc. 
Double Medical Technology, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






